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Blood platelets have been known for more than a century as important partners for successful metastatic
dissemination of solid tumors. Cancer cell-induced platelet activation is a key event responsible for
prometastatic activity of platelets. Blocking platelet aggregation inhibits the progression of skeletal
metastases through mechanisms that are not fully understood. The establishment and progression of
bone metastases are strongly inﬂuenced by the bone remodeling process. Growth factors and cytokines
released upon platelet activation may contribute to both skeletal tumor growth and osteolytic lesions.
Megakaryocytes are platelet precursors located in the bone marrow that control bone mass through
direct stimulation of osteoblast functions and indirect inhibition of osteoclast activities. Considering
growing evidence for their role in the metastatic cascade, platelets and/or megakaryocytes may provide
new therapeutic opportunities to help limit bone metastases.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Platelets and cancer metastasis
Blood platelets play a primary role in wound healing and he-
mostasis. Since the ﬁrst observation made (on himself) by the
surgeon A. Trousseau in the late 1800s, thrombosis is now ac-
cepted to be associated with poor cancer outcomes. Aspirin pre-
vents distant metastasis of adenocarcinomas that accounts for the
early reduction in cancer deaths in trials of daily aspirin versus
control [1]. Clear demonstration of platelets controlling metastasis
emerged in the mid-1900s through platelet depletion experiments
that remarkably inhibited the incidence of lung metastases in mice
[2]. Therefore, platelets are now considered as preeminent factors
of cancer metastasis. Metastatic tumor cells induce platelet ag-
gregation and embolus formation. In turn, platelets release a ple-
thora of factors that contribute to circulating tumor cell (CTC)
survival in a stressed condition generated in the bloodstream.
Shear stress and Natural Killer cytotoxic cells are the main threats
to CTCs inside the blood vessels [3]. At later steps of the metastatic
cascade, interaction of CTCs with platelets favors extravasation and
seeding of CTCs to distant organs. Platelets and endothelial cells
express several types of selectins that support transient CTC ad-
hesion to the vessel wall [4]. Plasma ﬁbrinogen and its platelet-GmbH. This is an open access art
Peyruchaud).speciﬁc receptor, αIIbβ3 integrin, also contribute to platelet-CTCs
emboli [5]. Both members of the β3 integrin family, platelet αIIbβ3
and tumor αVβ3, are involved in CTC adhesion and invasion under
ﬂow conditions [6]. In addition to contribute to multiple steps of
the metastatic cascade, platelets are also important modulators of
inﬂammation and angiogenesis. These aspects of platelet functions
are outside the scope of the present review but have been very
well described in recent publications [7,8].2. Platelets and bone remodeling
Clinical studies focused on the role of plasma rich platelets
(PRP) demonstrated the involvement of thrombocytes in bone
remodeling under acute and physiologic conditions [9]. Platelet
aggregates localize around the sites of fractures or micro-fractures,
wherein they release intragranular growth factors such as Platelet-
Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor
(VEGF), Insuline-Like Growth Factor 1 (IGF-1) or Transforming
Growth Factor 2 (TGFβ), all known to recruit osteogenic cells [10].
Thromboxane A2 (TxA2) and Prostaglandins were also identiﬁed
as bone remodeling modulators [9]. The role of platelets in os-
teoclastogenesis and bone resorption remains controversial. Sev-
eral studies showed that activated platelets and PRP can enhance
osteoclastogenesis via a RANKL-dependent mechanism [11],
whereas others showed inhibitory effects [12]. Such discrepanciesicle under the CC BY-NC-ND license
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platelets in vitro.3. Platelets and bone metastasis
It is now well established that platelets are essential for cancer
metastatic dissemination and progression to the bone, as revealed
by the seminal work using β3-deﬁcient mice that exhibited a 95%
decrease in skeletal tumor burden after intracardiac inoculation of
B16 melanoma cells [13]. The use of osteoclast defective src-/-mice
and speciﬁc platelet aggregation inhibitors could discriminate
between the roles of β3 integrins of osteoclasts and of platelets.
Integrin αIIbβ3 controls both platelet aggregation and CTC homing
to the bone microenvironment, whereas osteoclast integrin αVβ3
drives bone osteolysis [13]. Our group extended the role of platelet
αIIbβ3 integrin, not only to the onset of skeletal metastasis but
also to the progression of bone metastasis, by treating metastasis
harboring mice with integrilin, a pharmacological αIIbβ3 antago-
nist [14]. This study also revealed the role of platelet-derived ly-
sophosphatidic acid (LPA) as an enhancer of bone metastasis in
metastatic breast cancer models. LPA is a bioactive lipid that ex-
hibits growth factor-like activities by promoting proliferation,
survival migration and the secretion of pro-osteoclastic cytokines
[Interleukin 6 (IL-6) and 8, (IL-8), monocyte chimoattractant pro-
tein 1 (MCP-1), chemokine (C-X-C motif) ligand 1 (Groα)] [14]. LPA
is the ﬁnal product of the lysophospholipase D activity of auto-
taxin (ATX) that controls the physiological levels of LPA in blood.
We recently demonstrated that nontumoral circulating ATX can be
stored in α-granules of resting platelets and released upon breast
cancer cell stimulation contributing to metastasis formation [15].
Several anti-platelet therapies have been evaluated in the con-
text of bone metastasis. In vitro, a dual anti-platelet treatment using
the soluble ADPase APT102 and an inhibitor of TxA2 synthesis
(Aspirin) markedly affected tumor cell-induced platelet aggregation
without altering tumor cell viability. While in vivo, ATP102 and
Aspirin treatment did not affect primary tumor growth, the com-
bined treatment signiﬁcantly attenuated the melanoma and breast
cancer bone metastasis formation in mice [16].4. Megakaryocytes and bone mass acquisition
Mature Megakaryocytes (MKs) are located in the bone marrow
in vascular sinusoid areas where they undergo changes leading to
the production of platelets [17]. Knockout mice for the transcrip-
tion factors Nf-E2 and GATA-1 have marked and mild thrombo-
cytopenia, respectively, which in both cases are associated with an
increase in MK number revealing that Nf-E2 and GATA-1 are re-
quired for MK terminal differentiation and platelet production
[18]. Intriguingly, both Nf-E2-/-and GATA-1-/-mice exhibit high
bone mass phenotypes increased [Bone Mineral Density (BMD),
Bone Volume over Tissue Volume ratio (BV/TV), trabecular and
cortical thicknesses]. MKs produce a large variety of factors,
among them are bone regulators such as [Bone Morphogenetic
Protein-2,-4,-6 (BMP-2,-4,-6) and TGFβ] [19], which may account
for MK-stimulating bone formation. On the other hand, osteoblasts
secrete multiple cytokines that control hematopoiesis [Leukemia
Inhibitor Factor (LIF), Stem Cell Factor (SCF) and IL6] including MK
proliferation and differentiation [20]. Consequently, MK and os-
teoblasts could stimulate each other, establishing a “win-win” si-
tuation at localised bone sites. Osteoblast proliferation is enhanced
by MKs via a process regulated in part by integrin signaling (α3β1,
α5β1, αIIbβ3) controlling subcellular localization of the tyrosine
kinase Pyk2 in osteoblasts [21]. MKs also produce the physiological
osteoclast inhibitor Osteoprotegerin (OPG) that could explain theinhibitory effect of MK conditioned media on osteoclastogenesis
However, conditioned media collected from MKs derived from
OPG-/-mice also provides inhibition, thus minimizing the con-
tribution of OPG in the endogenous anti-osteoclastic activity of
MKs but conﬁrming the secretion of unidentiﬁed osteoclast in-
hibitors by MKs [22].5. Megakaryocytes and bone metastasis
Thrombopoietin (TPO) is a master regulator of
Megakaryocytopoiesis and platelet production [17]. Transgenic
mice overexpressing TPO exhibit an increase in MK number in the
bone marrow and develop a high bone mass phenotype [23]. TPO
inhibits osteoclast differentiation and their resorption activity in
vitro. Thus, in vivo TPO might inhibit osteoclast function both di-
rectly and indirectly through increased production of MK-derived
osteoclast inhibitors for inducing osteoclerosis [24]. The increased
expansion of MKs in BALB/c nude mice in response to a 5-day TPO
administration prior to the intracardiac injection of PC3 prostate
cancer cells remarkably decreases the extent of skeletal lesions
and tumor burden [25]. This unexpected result may be because
TPO primarily increases the production of platelets by MKs and
thrombocytosis create a more favorable metastatic environment
for PC3 cells in the circulation. The platelet-production-in-
dependent function of MKs might predominate in this phenom-
enon. Mouse primary MKs inhibit proliferation of prostate carci-
noma cell lines (PC3, C4-2b, VCaP) in in vitro co-culture systems.
Intercellular contacts between MKs and PC3 cells lead to down-
regulation of cyclinD1 in cancer cells and upregulation of pro-
apoptotic factors (such as ASC and DAPK1), favoring apoptosis and
inhibition of skeletal tumor growth. Therefore, the anti-tumor
effect of MKs in synergy with their anti-osteoclastic action is likely
the reason for inhibition of PC3 cell bone metastasis development.
Nonetheless, such an anti-metastatic activity of MKs has not been
reported in other types of organs and tissues. In contrast to their
action on prostate cancer cell lines, MKs stimulate the proliferation
of osteosarcoma cells [25]. Further experimental work is required
to determine whether the anti-bone metastasis activity of MKs
could be generalized to other types of solid tumors.
Intravenous injection of B16F10 melanoma cells in Nf-E2-/-mice
produces markedly less lung metastatic lesions compared to that in
wildtype mice [5]. This provides one of the strongest conﬁrmations for
the role of platelets in hematological dissemination of tumor cells al-
though bone tissues were not examined. The platelet-type von Will-
ebrand disease (Pt-vWD) is characterized by a higher afﬁnity of pla-
telets to the soluble form of von Willebrand factor due to a point
mutation in GPIbα to a persistent thrombocytopenia and a bleeding
disorder. Transgenic mice reproducing the Pt-vWD exhibit increasing
number of MKs and a high bone mass phenotype [26]. Due to its
speciﬁc expression in MKs and platelets, GPIbα has been suggested as
target for the development of new therapies against skeletal metas-
tasis. Nevertheless, the role of GPIbα in tumor cell-induced platelet
aggregation remains controversial, with some reports showing its
positive contribution [27], and others described no impact of blocking
GPIbα antibodies [28]. Also, in experimental metastasis models using
B16F10 melanoma cells, mice lacking GPIbα developed a lower
number of lung metastases than wild type mice [29]. In a striking
contrast, functional inhibition of GPIbα using monoclonal antibodies
in vivo led to a strong increase in pulmonary metastasis [30]. The
reason for these discrepancies remain to be established.
6. Conclusion
Due to their speciﬁc location in vascular sinusoids, MKs appear
as tempting targets for blocking skeletal metastases because they
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early steps of bone colonization. Although TPO blocks PC3-induced
skeletal metastasis in mice, such a regimen is unlikely to be
transferred to the clinic because of an immediate increase in the
circulating platelet count that could favor interactions between
tumor cells and platelets, thereby increasing the risk of venous
thromboembolism [31]. Targeting platelets and/or MKs may help
inhibiting cancer metastases to the bone. However, to achieve ef-
ﬁcacy and safety, strategies to block platelets’ prometastatic ac-
tivity will need to maintain platelets’ vital functions in hemostasis
while increasing the number of MKs in the bone marrow pre-
venting bone degradation and stimulating bone formation.Acknowledgements
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